GlassScriptPhysician profile
Daniel B Perkins
NPI 1124087556
$1,076.63
in general payments reported to CMS, 2019-2025
26 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $141 · 2021: $176 · 2022: $155 · 2023: $158 · 2024: $123 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $128.93 | 2019-2022 | |
| Abbvie INC. | $128.86 | 2021-2025 | |
| Lilly USA, LLC | $118.18 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $87.74 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $86.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $67.98 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $45.10 | 2022-2023 | Xarelto |
| Amgen INC. | $36.24 | 2022-2024 | Otezla, Repatha |
| Dexcom, INC. | $36.09 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.07 | 2023 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $29.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.70 | 2023 | Livalo, Seglentis |
| Inogen, INC. | $26.04 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $22.87 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $22.47 | 2023 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.84 | 2025 | Auvelity |
| Allergan, INC. | $19.73 | 2020 | |
| Exact Sciences Corporation | $18.98 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $18.94 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.48 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.21 | 2025 | Voquezna |
| Insulet Corporation | $14.23 | 2021 | |
| Pfizer INC. | $14.13 | 2024 | |
| Merck Sharp & Dohme LLC | $13.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.73 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.